Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Andrés J.M. Ferreri(Vita-Salute San Raffaele University), M. Dreyling(LMU Klinikum), Gerald Illerhaus(Klinikum Stuttgart), Khê Hoang‐Xuan(Sorbonne Université), Denis Malaise(Inserm), Maurilio Ponzoni(San Raffaele University of Rome), Kate Cwynarski(Royal London Hospital), Jacoline E. C. Bromberg(Erasmus MC), Mats Jerkeman(Skåne University Hospital), Elisabeth Schorb(University Medical Center Freiburg), C. Buske(University Hospital Ulm), Dorothee P. Auer(University of Nottingham), C. Soussain(Inserm), Christopher P. Fox(University of Nottingham), Lena Specht(University of Copenhagen), Teresa Calimeri(Harvard University), Emanuele Zucca(Università della Svizzera italiana), Jeanette K. Doorduijn(Erasmus MC Cancer Institute)

Annals of Oncology

June 1, 2024

10.1016/j.annonc.2023.11.010

Cited by 46

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

|Blood|2022|1.5k

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

|The Lancet|2005|1k

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

|The Lancet Oncology|2016|738

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2017|736